Resources
Unlocking New E3 Ligases for Targeted Protein Degradation in Cancer Therapy
Case Study
Posted on Sep 06, 2024
Driving circRNA Analysis with Strand’s Solutions
Case Study
Posted on Aug 01, 2024
Streamlining Germline Testing: Pipeline Development and Clinical Variant Interpretation
Case Study
Posted on Jul 17, 2024
Comprehensive End-to-End Solutions for a Pet NGS Diagnostic
Case Study
Posted on Jul 16, 2024
Workflow Management Systems: Our Software Solutions using Nextflow and Snakemake
Case Study
Posted on Mar 29, 2024
Strand-Agilent Mass Profiler Professional
Case Study
Posted on Mar 29, 2024
Spatial Transcriptomics: Our Path to 10X Genomics Visium Certification
Case Study
Posted on Mar 29, 2024
Somatic Variant Database Curation
Case Study
Posted on Mar 29, 2024
Ground Truth Dataset Curation for a Major Diagnostics Company
Case Study
Posted on Mar 29, 2024
Data Harmonization for a Big Pharmaceutical Company
Case Study
Posted on Mar 29, 2024
A Saliva-based Liquid Biopsy Assay for Oral Cancer
Case Study
Posted on Mar 29, 2024
Strand's qPCR Reporting Software
Case Study
Posted on Mar 29, 2024
Provider Portal & Electronic Data Capture Portal
Case Study
Posted on Mar 29, 2024
NGS Analysis Pipeline Development
Case Study
Posted on Mar 29, 2024
Our
Featured
Publications
Clinical Chemistry
Aug 2021
Determining Cost-Optimal Next-Generation Sequencing Panels for Rare Disease and Pharmacogenomics Testing
Multi-gene panel sequencing using next-generation sequencing (NGS) methods is a key tool for genomic medicine. However, with an estimated 140,000 genomic tests available, current system inefficiencies result in high genetic-testing costs.
BMC Medical Genomics
Apr 2021
Validation of whole genome sequencing from dried blood spots
Dried blood spots (DBS) are a relatively inexpensive source of nucleic acids and are easy to collect, transport, and store in large-scale field surveys, especially in resource-limited settings. However, their performance in whole-genome sequencing (WGS) relative to that of venous blood DNA has not been analyzed for various downstream applications.
Cancer Medicine
Sep 2018
Analysis of solid tumor mutation profiles in liquid biopsy
Liquid biopsy is increasingly gaining traction as an alternative to invasive solid tumor biopsies for prognosis, treatment decisions, and disease monitoring. Matched tumor-plasma samples were collected from 180 patients across different cancers with >90% of the samples below Stage IIIB.
Breast Cancer Research and Treatment
Feb 2018
Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations
Breast and/or ovarian cancers are among the most common cancers in women across the world. In the Indian population, the healthcare burden of breast and/or ovarian cancers has been steadily rising, thus stressing the need for early detection, surveillance, and disease management measures. However, the burden attributable to inherited mutations is not well characterized.
Cancer Medicine
Apr 2017
StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors
Comprehensive genetic profiling of tumors using next-generation sequencing (NGS) is gaining acceptance for guiding treatment decisions in cancer care. We designed a cancer profiling test combining both deep sequencing and immunohistochemistry (IHC) of relevant cancer targets to aid therapy choices in both standard-of-care (SOC) and advanced-stage treatments for solid tumors.
download the case study.